Skip to content
Screener

EPS (Basic) at other companies

Myriad Genetics logo
Myriad GeneticsMYGN
-$0.36
Labcorp Holdings logo
Labcorp HoldingsLH
$3.66+28.4%
Opko Health logo
Opko HealthOPK
-$0.01+94.7%
NeoGenomics logo
NeoGenomicsNEO
$0.02+106%
Exagen Inc. logo
Exagen Inc.XGN
-$0.17+15.0%
Personalis, Inc. logo
Personalis, Inc.PSNL
-$0.29-61.1%

Other financials

Income statement

See full
Revenue$3.0B+10.2%
Gross profit$1.0B+8.9%
Operating income$459.0M+4.8%
Net income$320.0M+13.5%
EPS (diluted)$2.84+15.0%

Balance sheet

See full
Cash & equivalents$626.0M+96.2%
Total debt$6.4B0.0%
Total equity$7.5B+4.0%
Total assets$16.9B+6.1%

Cash flow

See full
Operating cash flow$597.0M+9.7%
CapEx$138.0M+27.8%
Free cash flow$459.0M+5.3%

Valuation

See full
Market cap$26.32B+36.1%
Enterprise value$32.08B+26.3%
P/E24.8×+4.4×
P/S2.3×+0.4×

Profitability

See full
Gross margin33.1%+0.1pp
Operating margin14.1%+0.1pp
Net margin9.2%+0.2pp
FCF margin11.7%0.0pp

Returns & leverage

See full
Return on equity14.4%+0.7pp
Debt / equity0.8×0.0×
Current ratio1.6×+0.5×

Where this comes from

Reported directly by Quest Diagnostics in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The source filing: Quest Diagnostics’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 4:16 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001022079-26-000070
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Less: Net income attributable to noncontrolling interests14142629
Net income attributable to Quest Diagnostics$320$282$572$502
Earnings per share attributable to Quest Diagnostics’ common stockholders:
Basic$2.88$2.51$5.15$4.48
Diluted$2.84$2.47$5.08$4.41
Weighted average common shares outstanding:
Basic111112110112
Diluted112113112113

Cover / Front Matter

FAQ

What is Quest Diagnostics's EPS (basic)?
Quest Diagnostics (DGX) reported EPS (basic) of $2.88 in Q2 2026.
How has Quest Diagnostics's EPS (basic) changed year-over-year?
Quest Diagnostics's EPS (basic) increased by 14.7% year-over-year, from $2.51 to $2.88.
What is the long-term trend for Quest Diagnostics's EPS (basic)?
Over 4 years (2021 to 2025), Quest Diagnostics's EPS (basic) has grown at a -13.6% compound annual growth rate (CAGR), from $15.90 to $8.87.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.

Ask your AI about Quest Diagnostics's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude